Severe recalcitrant morbilliform eruption from dual immune checkpoint blockade.
JAAD Case Rep
Immune checkpoint inhibitors represent one of the newest and most promising therapies for malignancy, but they place patients at risk for autoimmune sequelae, including cutaneous eruptions. M7824, a novel bifunctional fusion protein currently in clinical trials, is directed against both programmed cell death ligand 1 (PD-L1) and transforming growth factor beta (TGF-β). It is well known that PD-1 checkpoint inhibition may lead to symptomatic cutaneous eruptions that most often can be effectively managed without discontinuation of antitumor therapy.1 Here we report a case of a severe, recalcitrant morbilliform eruption that began after dual immune checkpoint blockade with M7824 infusion.